Kodiak Sciences (Kodiak Sciences) Debt-to-Asset : 0.17 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Kodiak Sciences Debt-to-Asset?

Kodiak Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $9.77 Mil. Kodiak Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $71.86 Mil. Kodiak Sciences's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $479.37 Mil. Kodiak Sciences's debt to asset for the quarter that ended in Dec. 2023 was 0.17.

Kodiak Sciences Debt-to-Asset Historical Data

The historical data trend for Kodiak Sciences's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kodiak Sciences Debt-to-Asset Chart

Kodiak Sciences Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.01

0.07

0.09

0.13

0.17

Kodiak Sciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial															0.13	0.14	0.14	0.15	0.17

Competitive Comparison of Kodiak Sciences's Debt-to-Asset

For the Biotechnology subindustry, Kodiak Sciences's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kodiak Sciences's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kodiak Sciences's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Kodiak Sciences's Debt-to-Asset falls into.

Kodiak Sciences Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Kodiak Sciences's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(9.77	+	71.862)	/	479.372
	=	0.17

Kodiak Sciences's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(9.77	+	71.862)	/	479.372
	=	0.17

Kodiak Sciences (NAS:KOD) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Kodiak Sciences Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Kodiak Sciences's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Kodiak Sciences (Kodiak Sciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kodiak Sciences Inc (NAS:KOD) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

K27:Germany

Address

1200 Page Mill Road, Palo Alto, CA, USA, 94304

Website

https://www.kodiak.com

Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.

Executives

Jason Ehrlich	officer: See Remarks	1200 PAGE MILL ROAD, PALO ALTO CA 94304
John A. Borgeson	officer: See Remarks	1200 PAGE MILL ROAD, PALO ALTO CA 94304
Baker Bros. Advisors Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Victor Perlroth	director, 10 percent owner, officer: Chairman, President and CEO	1200 PAGE MILL ROAD, PALO ALTO CA 94304
Julian Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Felix Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667,	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors (gp) Llc	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Charles A Bancroft	director	BRISTOL-MYERS SQUIBB COMPANY, ROUTE 206 & PROVINCE LINE ROAD, PRINCETON NJ 08543
Hong Liang	officer: See Remarks	2631 HANOVER STREET, PALO ALTO CA 94304
Richard S Levy	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Taiyin Yang	director	2631 HANOVER STREET, PALO ALTO CA 94304
Robert Profusek	director	P.O. BOX 696000, SAN ANTONIO TX 78269-6000
Bassil I Dahiyat	director	C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016